Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors.
Volgraf, M., Chan, L., Huestis, M.P., Purkey, H.E., Burkard, M., Geck Do, M., Harris, J., Hunt, K.W., Liu, X., Lyssikatos, J.P., Rana, S., Thomas, A.A., Vigers, G.P., Siu, M.(2014) Bioorg Med Chem Lett 24: 2477-2480
- PubMed: 24780121 
- DOI: https://doi.org/10.1016/j.bmcl.2014.04.012
- Primary Citation of Related Structures:  
4PZW, 4PZX - PubMed Abstract: 
The development of 1,3,4,4a,5,10a-hexahydropyrano[3,4-b]chromene analogs as BACE1 inhibitors is described. Introduction of the spirocyclic pyranochromene scaffold yielded several advantages over previous generation cores, including increased potency, reduced efflux, and reduced CYP2D6 inhibition. Compound 13 (BACE1 IC50=110 nM) demonstrated a reduction in CSF Aβ in wild type rats after a single dose.
Organizational Affiliation: 
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States. Electronic address: volgrafm@gene.com.